Mainz, Rhineland-Palatinate, Germany
Development of meaningful humanized mouse models for pre-clinical testing of monoclonal antibodies and new Biologicals to regulate of exuberant or imbalanced immune responses in humans Dendritic cell-based immunotherapy of cancer (especially melanoma) Nanoparticle-based immunotherapy of cancer Development and improvement of human regulatory T cells as a therapeutic option for treatment of GvHD, Multiple Sclerosis, Rheumatoid Arthritis, and Psoriasis. Clinical development of the Treg activator GP120 including ATMP. Cellular therapies using activated regulatory T cells to treat inflammatory autoimmune diseases and transplant rejection. Dendritic cells: Development & Differentiation Human regulatory T cells: Subsets, Function, Modulation
studentische Lehrveranstaltungen Etatplanung, Abteilungsleitung, Forschung & Entwicklung
Basic research, Research Strategy Development, translation of research results to patients, third-party funds, project management of various research projects, research organization and funding, clinical implementation of industrial property rights, advice on research matters, Education and Teaching
ActiTrexx, a designated spin-out of the University Medical Center Mainz, Germany, focuses on the development and commercialization of the cellular therapy ATreg for the treatment of patients after hematopoetic stem cell transplantation (HSCT) to prevent graft-versus-host disease (GvHD).
Forschungsorganisation, Struktur und Investitionsplanung Organisation der studentischen Ausbildung, Curriculum, Projektplanung, Verwendung der Forschungsmittel
Jan 2010 – Dec 2015 - Immunomodulation by dysbalanced immune responses - Functional characterization of human dendritic cells and regulatory T cells - Development of efficient dendritic cell-based cellular therapies of cancer - T cell modulatory compounds for treatment of allergy, autoimmunity and chronic inflammatory diseases Feb 2002 – present Research Director University Medical Center of the Johannes Gutenberg-University Mainz, Department of Dermatology, Mainz, Germany Jan 1991 – Dec 2012 Johannes Gutenberg-University Mainz, Department of Dermatology, Mainz, Germany Dendritic cell biology, dendritic cells in tumor immunity, dendritic cell-based immunotherapy of melanoma, regulatory T cells: human subsets, gene regulation, transcriptional regulation, biologics to modify Treg activity, humanized mouse models Jan 2014 - present Clinical development of the Treg activator gp120 for treatment of transplant rejection, GvHD and autoimmune diseases Commercialization of a Treg activator and biomarkers for identification of Treg-sensitive patients